Taysha Gene Therapies, Inc.

NASDAQ:TSHA

Biotechnology

Healthcare
$3.77 +1.53%

+$0.10 today

Market cap
$1.22B
Beta
1.18
P/E (TTM)
-17.7
EPS (TTM)
-$0.35
52W Low $2.25High $7.30

Volume 2.17M

Average 2.73M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$93.09M

FY 2025 · Annual

Investing Cash Flow

-$604,000.00

FY 2025 · Annual

Financing Cash Flow

$274.59M

FY 2025 · Annual

+258.1% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(174.52M)(166.01M)(111.57M)(89.3M)(109M)
Depreciation & Amortization492K1.17M1.37M1.25M1.15M
Deferred Income Tax00000
Stock-Based Compensation18.18M18.04M7.91M13.1M13.3M
Change in Working Capital28.67M18.52M(18.01M)(12.47M)(5.37M)
Accounts Receivables00000
Inventory00000
Accounts Payables14.49M(7.8M)(2.3M)(2.92M)(153K)
Other Working Capital14.17M26.32M(15.72M)(9.55M)(5.22M)
Other Non-Cash Items10.14M39.89M47.28M6.19M6.83M
Operating Cash Flow(117.04M)(88.39M)(73.02M)(81.23M)(93.09M)
Capital Expenditures(21.55M)(24.87M)(7.37M)(374K)(738K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(6.25M)(61K)(3.48M)11K134K
Investing Cash Flow(21.55M)(24.93M)(7.35M)(363K)(604K)
Debt Repayment39.96M0(3.45M)09.24M
Common Stock Issued(360K)53.24M140.79M76.78M265.69M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(514K)(1.15M)(947K)(96K)(337K)
Financing Cash Flow39.08M52.1M136.39M76.68M274.59M
Effect of Forex Changes00000
Net Change in Cash(99.51M)(61.22M)56.02M(4.9M)180.9M
Free Cash Flow(138.6M)(113.26M)(80.39M)(81.6M)(93.83M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$109.0M
+ D&A$1.1M
+ Stock-Based Comp$13.3M
+ Deferred Tax$0
- Working Capital-$5.4M
+ Other Non-Cash$6.8M
= Operating Cash Flow-$93.1M
- Capex-$738.0K
= Free Cash Flow-$93.8M

Analysis

FY2025 free cash flow is -$93.8M. FCF conversion is 86.1% of net income. Operating cash flow was -$93.1M, with capex of -$738.0K. The largest bridge item is Stock-Based Comp at $13.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 12, 2026
8-KCurrent reportNov 12, 2026
SC 13G/ASC 13G/A filingAug 14, 2026
SC 13G/ASC 13G/A filingAug 13, 2026
10-QQuarterly reportAug 11, 2026

Does TSHA generate free cash flow?

Taysha Gene Therapies, Inc. (TSHA) generated -$93.83M of free cash flow in fiscal 2025.

How much operating cash flow does TSHA produce?

Operating cash flow was -$93.09M, before capital expenditures of $738,000.00.